Corteva, Inc.

ΔGM = β·Δlog(pata) + ε con β y φ(AR1 de ε) reestimados walk-forward solo con trimestres ya publicados; el residuo agrupa coste unitario, mix y volumen

• Corteva may not be able to obtain or maintain the necessary regulatory approvals for some of its products, including its seed and crop protection products, which could restrict its ability to sell those products in some markets.
• The successful development and commercialization of Corteva's pipeline products will be necessary for Corteva's growth.
• The degree of public understanding and acceptance or perceived public acceptance of Corteva’s biotechnology and other agricultural products and technologies can affect Corteva’s sales and results of operations by affecting planting approvals, regulatory requirements and customer purchase decisions.
• Corteva’s business is subject to various competition and antitrust, rules and regulations around the world, and as the size of its business grows, scrutiny of its business by legislators and regulators in these areas may intensify.
• Changes in agricultural and related policies of governments and international organizations may prove unfavorable.
• Climate change and unpredictable seasonal and weather factors could impact Corteva’s sales and earnings.
• Corteva participates in an industry that is highly competitive and has undergone consolidation, which could increase competitive pressures.
• nuevoRecent funding and staff reductions, including at the EPA, the USDA, the FDA and the U.S. Department of Health and Human Services ("HHS"), could hinder our ability to receive timely regulatory approvals.
• Corteva’s sales to its customers may be adversely affected should a company successfully establish an intermediary platform for the sale of Corteva’s products or otherwise position itself between Corteva and its customers.
• Our business, financial condition and results of operations could be materially affected by disruptions in the global economy caused by geopolitical and military conflicts.
• Volatility in Corteva’s input costs, which include raw materials and production costs, could have a significant impact on Corteva’s business, results of operations and financial condition.
• Corteva’s operations outside the United States are subject to risks and restrictions, which could negatively affect Corteva’s business, results of operations and financial condition.
• Corteva’s business, results of operations and financial condition could be adversely affected by industrial espionage and other disruptions to its supply chain, information technology or network systems.
• Corteva is dependent on its relationships or contracts with third parties with respect to certain of its raw materials or licenses and commercialization.
• Corteva’s customers may be unable to pay their debts to Corteva, which could adversely affect Corteva’s results.
• Failure to effectively manage acquisitions, divestitures, strategic investments, restructurings, cost savings initiatives and other portfolio actions may not have the results anticipated.
• Corteva’s liquidity, business, results of operations and financial condition could be impaired if it is unable to raise capital through the capital markets or short-term debt borrowings.
• Increases in pension and other post-employment benefit plan funding obligations may adversely affect Corteva’s results of operations, liquidity or financial condition.
• Global or regional health pandemics or epidemics could negatively impact the company's business, financial condition and results of operations.
• Sentiment towards sustainability matters could adversely affect our stock price, results of operations, and access to capital.
• Enforcing Corteva’s intellectual property rights, or defending against intellectual property claims asserted by others, could materially affect Corteva’s business, results of operations and financial condition.
• Corteva’s business may be adversely affected by the availability of counterfeit products.
• Restrictions under the intellectual property cross-license agreements limit Corteva’s ability to develop and commercialize certain products and services and/or prosecute, maintain and enforce certain intellectual property.
• nuevoThe Corteva Separation and related transactions may expose Corteva to potential liabilities arising out of state and federal fraudulent conveyance laws
• The company is subject to continuing contingent tax-related liabilities of DowDuPont following the Distribution.

encabezados en negrita/cursiva del HTML que aparecen dentro del Item 1A y van seguidos de ≥300 caracteres de cuerpo (así se descartan los encabezados de grupo); categorías por mapa fijo de palabras clave; 'nuevo' = ausente del 10-K anterior. Sin LLM. Caveat: algún encabezado de grupo puede sobrevivir si su primer subtítulo no venía resaltado en el HTML. · accession 0001755672-26-000004